Allarity Therapeutics has received notice from the Securities and Exchange Commission that an enforcement action is pending regarding FDA meetings the biotech had surrounding the new drug application for cancer therapy dovitinib.

Having had to give up on its liver disease ambitions due to a lack of funds, Hepion Pharmaceuticals has decided that its best option is to merge into Israeli biotech Pharma Two B.

Innovent has pulled off another late-phase win for its Eli Lilly-partnered GLP-1 drug candidate, linking the dual agonist to improved outcomes in type 2 diabetes to tee up a filing for approval in China.

As Intuitive Surgical continues to roll out its latest da Vinci robot, following its launch in March, the company warned that supplies may be tight for the next 12 months.

Since the first patient received allogeneic hematopoietic cell transplantation (allo-HCT) to treat thalassemia, an inherited blood disorder affecting hemoglobin, in 1982, the therapy has rapidly grown in popularity. More than 8,000 transplants took place in 2021 according to the National Marrow Donor Program, and the procedure is now used to treat various blood cancers, inherited diseases, and sickle cell disease.

Artiva Biotherapeutics has upsized its IPO to $167 million as the allogeneic natural killer (NK) cell therapy prepares to list on the Nasdaq this morning.

Though his real name isn’t known, there’s no doubt that he’ll go down in history. An adult man dubbed “The Next Berlin Patient” has been declared the seventh person to be cured of HIV, and his case provides valuable information that could lead to a more broadly accessible approach for the 39 million people living with the virus around the globe.

Low double-digit growth in quarterly medical device sales has pushed Abbott to nudge up its earnings projections for the year.

After mulling over the data from a failed phase 2 trial, Johnson & Johnson has decided to halt development of its Addex Therapeutics-partnered epilepsy drug, Fierce Biotech has learned.

A $21 million public-private project led by the Foundation for the National Institutes of Health (FNIH) will see government agencies, nonprofits and industry giants hunt for biomarkers that distinguish Parkinson’s diseases from similar conditions.